|
Manufacturing review of the cangaroo envelope device history record for the reported lot shows that all packaged and labeled units were released to distribution on (b)(6) 2020 having met all internal qc acceptance requirements.All sterilization processing records and bioburden testing indicate a successful sterilization cycle, and passing results for product lal and sterility samples allowed this subassembly lot to be released for further packaging and labeling.One non-conformance was associated with this lot, however it was issued to allow implementation of new 510(k) issuance for shelf life.This non-conformance had no impact on the sterility or lal results or the final acceptance criteria for this manufacturing lot.In lieu of a request for oem supplier dhr review for ecm lot, it is noted that aziyo processes the non-sterile envelope materials including cutting, suturing, packaging, and sterilizing the product.The returned sample was not capable of being evaluated for the reported event (not in envelope form etc.) and it would have provided no additional information to this investigation.No product defect was noted (e.G.Package breach, damage etc.), and infection is a known complication of the surgical procedure and implantation of a cied device with cangaroo.It is noted that per the instructions for use (art-20662) provided with the finished cangaroo envelope, that infection is listed as a potential complication associated with the procedure and device.Although the exact cause of the reported infection cannot be conclusively determined at this time, should any additional details be received by aziyo relating to this event, a supplemental report will be filed.
|